Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...

Respiratory syncytial virus was linked to elevated incidence of cardiovascular events in older adults. Future research will help decide whether vaccination could reduce the impact of RSV on the heart.

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Two AS01-adjuvanted vaccines for different pathogens -- the respiratory syncytial virus (RSV) vaccine (Arexvy) and the ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

The Vaccine Integrity Project will convene experts to assess the evidence on influenza, RSV, and Covid-19 to equip clinicians ...

Compared with flu vaccine recipients, those given the RSV or shingles vaccine had 18% to 37% lower odds of receiving a ...

The medicines regulator has issued a warning to NHS health staff about a small increased risk of a rare condition affecting the nerves in people vaccinated against respiratory syncytial virus ...

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence. HealthDay News — Nirsevimab is effective for reducing the burden ...

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in clinical trials.

Fact checked by Jennifer Klump A group of advisors to the Centers for Disease Control and Prevention (CDC) voted 5-2 to ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s Enflonsia.